Zynext Ventures USA, the venture capital arm of Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321), has agreed to invest of an undisclosed amount in biopharmaceutical company Illexcor Therapeutics.
The investment is aimed at advancing novel oral therapy for sickle cell disease, according to a Wednesday filing to the Indian stock exchanges.
Illexcor is developing oral therapies for sickle cell disease. The lead asset, currently in preclinical development, is designed to bind to Hemoglobin S and effectively block polymerization and sickling, offering the potential for disease-modifying clinical benefits.
Zydus Lifesciences shares were up nearly 1% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。